Background {#Sec1}
==========

Shockwave Therapy (SWT) is used to treat a range of musculoskeletal conditions. Focused and radial shockwave (radial pressure waves) are two technically distinct forms of SWT. It has been argued that focused shockwave therapy and radial shockwave therapy should be viewed as distinctly different therapeutic modalities \[[@CR1]\]. However, despite the differences in their physical characteristics, method of energy generation and shockwave propagation, focused and radial shockwave types share common clinical indications \[[@CR2]\]. SWT is often indicated as a secondary conservative treatment choice for recalcitrant musculoskeletal conditions, unresponsive to standard care \[[@CR1], [@CR3]\]. These indications include plantar fasciitis, Achilles tendinopathy, patellar tendinopathy, calcific and non-calcific shoulder tendinopathy and lateral epicondylitis. Also, bone and cartilage related disorders such as non-union of fractures, osteonecrosis of the femoral head and knee osteoarthritis related bone marrow edema (BME) are among the range of SWT clinical indications. Research evidence for SWT clinical effectiveness varies across the indicated conditions. Good evidence based on systematic reviews exists to support the use of SWT for calcific tendinopathy of the shoulder \[[@CR4]\], Achilles tendinopathy \[[@CR5], [@CR6]\], knee osteoarthritis \[[@CR7]\], early stage osteonecrosis of the femoral head \[[@CR8]\] and plantar fasciitis \[[@CR9]\]. However, research evidence for the effectiveness of SWT in lateral epicondylitis is variable \[[@CR1]\] and is lacking for patellar tendinopathy \[[@CR3], [@CR6]\].

Focused shockwaves are generated through three mechanisms: electrohydraulic, piezoelectric or electromagnetic methods that convert electrical energy into kinetic energy, whilst radial shockwaves are generated pneumatically \[[@CR2]\]. The proposed mechanism of action for SWT is based on mechano-transduction \[[@CR10]\]. The delivery of mechanical acoustic energy to the target tissue induces molecular, cellular and tissue responses \[[@CR11]\]. Based on animal studies, SWT promotes the expression of various angiogenic and osteogenic growth factors such as vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP), which promotes tissue regeneration \[[@CR12]\]. In addition, SWT has an anti-inflammatory effect by modulating the expression of interleukins (IL-6 and IL-10) and other cytokines \[[@CR13]\].

Clinical outcomes such as pain rating and functional disability scores are commonly used to evaluate the effectiveness of SWT. However, the utilization of objective outcome measures that evaluate changes in the affected musculoskeletal tissues is required to provide evidence of SWT influence on pathophysiological processes in humans. Different imaging techniques are used clinically to establish a diagnosis, guide the delivery of an intervention or to evaluate the effectiveness of an intervention. A range of imaging modalities including magnetic resonance imaging (MRI), ultrasonography (US), Computed Tomography (CT), dual-energy x-ray absorptiometry (DEXA) or plain radiography have been used to support diagnosis and in some cases to evaluate outcomes in studies investigating SWT. Despite lack of consistency in utilization, these imaging modalities are valuable tools for evaluating the morphological characteristics of injured tissues. That can then be used clinically to monitor improvements in the underlying pathophysiological process following an intervention. Therefore, the utilization of suitable imaging tools at appropriate time points as an adjunct to clinical examination may provide a better understanding of the tissue pathophysiology and support the management planning process. Little is known about the capacity of SWT to induce positive improvements in pathophysiological processes in musculoskeletal disorders, as indicated by changes in imaging parameters and no systematic reviews have been conducted on this topic. Therefore, the primary aim of this review was to explore the available evidence from clinical prospective trials with regard to any changes in the morphology of musculoskeletal lesions following SWT, as measured by imaging parameters. The secondary aim was to investigate significant predictors for the SWT effects using meta-regression. We also sought to make recommendations for future research studies.

Methods {#Sec2}
=======

Protocol and registration {#Sec3}
-------------------------

This systematic review and meta-analysis was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). The protocol of the current review was registered on the International Prospective Register of Systematic Reviews (PROSPERO; 2018, CRD42018091140).

Search strategy {#Sec4}
---------------

A comprehensive search using the electronic databases of MEDLINE, EMBASE, CINAHL, SPORTDiscuss and the Cochrane Controlled Trials Register using the PICOS format (population, intervention/exposure, comparison, outcome and study design) was conducted in October 2018. A range of keywords integrated with subject headings relevant to the review were systematically searched to maximize the search results. Keywords for the population category contained terms related to musculoskeletal conditions such as arthritis, fractures, bone marrow edema and tendinopathies. The intervention category contained keywords related to shockwave therapy. The outcome category contained terms related to different imaging methods (e.g. X-ray, MRI, Ultrasound imaging). No specific comparator was added as the primary aim of the review was to examine post intervention imaging changes. An example of the basic search strategy for databases is presented in Additional file [1](#MOESM1){ref-type="media"}.

Eligibility criteria included prospective study designs to avoid any potential selection bias inherent in retrospective studies, adult participants of both genders with an established musculoskeletal diagnosis and reported pre and post imaging measures to facilitate evaluation of changes in affected tissue morphology following SWT of any type (focused and radial). Non-human and non-English language studies were excluded.

Study identification {#Sec5}
--------------------

The principal author conducted the database search. Study screening was carried out using the Covidence platform \[[@CR14]\]. Two independent reviewers (HA and SA) screened titles and abstracts to determine eligibility for inclusion. The decision to include or exclude studies, based on the eligibility criteria, was made independently by each author. Full-texts of potentially relevant studies were retrieved for further assessment. Discrepancies in opinions were resolved by a third senior reviewer (AW).

Risk of bias assessment {#Sec6}
-----------------------

The quality of studies was independently evaluated by two reviewers (HA and SA). A third senior reviewer (AW) was involved to resolve differences in assessment. Randomized Controlled Trials (RCTs) were evaluated using the Cochrane Risk of Bias list \[[@CR15]\]. The tool evaluates the risk of bias in five domains (selection, performance, attrition, reporting and other) for seven elements to be judged as high, unclear or low risk. A three-point scale was used to assign each degree of risk a number value with higher numbers indicating a lower risk of bias (low risk = 2, unclear risk = 1 and high risk = 0). The maximum score of 14 indicates the lowest risk of bias for a given study.

The Methodological Index for Non-Randomized Studies (MINORS) tool \[[@CR16], [@CR17]\] was used to evaluate the non-randomized studies. The MINORS is a valid and reliable tool that contains 12 methodological items, the first eight items measure attributes specific to non-comparative studies. Four additional items are evaluated only for studies with comparative groups. A higher score indicates a lower risk of bias.

The risk of bias was assessed mainly at the reported measured imaging outcomes level. The score for each risk of bias tool was divided by the total number of points possible to calculate the risk of bias percentage for each study.

Data extraction {#Sec7}
---------------

One reviewer (HA) extracted relevant data from individual studies and the data were independently checked by a second reviewer (SA) for consistency. Extracted data included study characteristics such as study design, participant numbers and demographics, the condition treated, parameters and dosage of the SWT intervention (level of energy, number of shocks and sessions), follow-up period, imaging modality description and findings. Authors were contacted when relevant outcomes were incompletely reported and were asked to provide missing information. When the values of standard deviations (SD) were not provided for the intervention or control group, these were calculated from confidence intervals, and *p*-values for differences in means, or for group means using the RevMan calculator \[[@CR18]\].

Primary outcome {#Sec8}
---------------

Changes in measures derived from imaging methods such as MRI, ultrasonography, CT, DEXA or plain radiography reflecting morphological changes in affected musculoskeletal tissues following SWT were the primary evaluated outcomes for this review. The measures of effect were pre to post-imaging changes, demonstrating presence, grade, signal intensity or size of the tissue lesion. The strategy for data synthesis employed a quantitative method in the form of meta-analysis depending upon the type of data extracted, alongside narrative qualitative synthesis. The method of evaluation for each study is clearly stated in the relevant tables.

Statistical analysis {#Sec9}
--------------------

Quantitative data analysis was performed using RevMan \[[@CR18]\]. Meta-analysis was conducted to calculate pooled effect size for included studies. Continuous data were presented as mean differences (MD) and dichotomous data with odds ratios (OR), including the corresponding 95% confidence interval (CI). Pooling was performed using a random effects model to provide summary effect size owing to expected clinical and methodological heterogeneity. Subgroup analyses were performed separately for each musculoskeletal condition based on SWT type or dosage, control group or use of imaging guidance. Heterogeneity was assessed statistically with χ^2^ test and I^2^ statistics and significance was set at *p* \< 0.05. Meta-regression was carried out to explain the source of heterogeneity based on important mediating covariates such as SWT dose parameters, baseline lesion size, utilization of anesthesia and imaging guidance (determined a priori).

Results {#Sec10}
=======

Study selection and characteristics {#Sec11}
-----------------------------------

The database searches resulted in 789 titles. (Fig. [1](#Fig1){ref-type="fig"}). Following the removal of duplicates and exclusion of records based on title and abstract screening, a total of 93 studies were available for full-text review. A total of 30 studies were further excluded with inappropriate study design (predominantly retrospective studies) or lack of imaging outcome as the most frequent reasons for exclusion, leaving a final selection of 63 studies meeting the inclusion criteria. Of the included studies, 30 used an RCT design and the remaining 33 studies were prospective cohort trials. Fig. 1PRISMA flow chart of study selection process

Description of included studies {#Sec12}
-------------------------------

The total number of participants in the SWT groups (focused and radial SWT) was 3110. The most commonly evaluated musculoskeletal condition was rotator cuff calcific tendinitis (23 studies), followed by plantar fasciitis (13 studies), femoral head necrosis (12 studies) and fracture non-union (4 studies). There were a few other individual studies evaluating different musculoskeletal conditions (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Musculoskeletal conditions of included studies

Quality assessment {#Sec13}
------------------

The risk of bias assessment is summarized in Additional file [2](#MOESM2){ref-type="media"} for included RCTs and prospective trials respectively. The mean score (%) ± SD of the Cochrane risk of bias tool among the 31 RCT studies was 59.68 ± 18.95, while the mean score was 73.61 ± 7.65 for non-RCT studies according to the MINORS tool. Items of risk of bias rating across all included RCT and non-RCT studies are shown in Additional file [2](#MOESM2){ref-type="media"}. Inter-rater reliability of the risk of bias assessment was calculated using the kappa coefficient (k). The overall agreement between the two primary reviewers was 79.84% (k = 0.53) indicating moderate agreement.

Rotator cuff calcific tendinitis {#Sec14}
--------------------------------

There were 23 studies (8 RCTs) published between 1995 and 2017 evaluating the effect of SWT on rotator cuff calcific tendinitis. The total sample was 1110 (1141 shoulders) participants. The main imaging inclusion criterion for participant recruitment was the presence of symptomatic type I or II calcification of the rotator cuff based on the Gartner and Simons radiographic classification \[[@CR19]\], as detected on radiographs. Detection of glenohumeral or acromioclavicular arthritis, rotator cuff tear or type III calcification were the main exclusion criteria.

Focused type SWT was used in 21 studies, while two studies used radial type SWT. The mean ± SD SWT delivered shocks was 2104 ± 990.57 (1000--6000) and the mean energy flux density (EFD) was 0.26 ± 0.15 (0.02--0.6) mJ/mm^2^. The mean number of SWT sessions was 2.66 ± 1.91 (1--8) with 10.1 ± 7.26 (1--35) days interval between sessions. Ten studies used anesthesia prior to SWT application and 14 studies used imaging guidance to target calcium deposits. Further details on included studies characteristics and SWT parameters are presented in Table [1](#Tab1){ref-type="table"}. Table 1Characteristics of studies and intervention details for rotator cuff calcifying tendinitisAuthor (year)Study designNMean age ±SD or (range)Mean symptoms duration ± SD or (range), monthsArea of SWT applicationDosage in impulses\*EFD (mJ/mm^**2**^)/barNo. of sessionsInterval between sessionsCo- intervention, anesthesiaAlbert (2007) \[[@CR20]\]RCT40 each groupHigh SWT: 46.6 (31--64)Low SWT: 47.5 (32--69)High SWT: 41.2 (6--120)Low SWT: 36.4 (7--160)Calcific deposit was identified using fluoroscopyHigh SWT: 2000\*0.45Low SWT: 2000\*0.02214 daysNone, yesCacchio (2006) \[[@CR21]\]RCT4556.12 ± 1.9814 ± 4.95Seated with shoulder abducted at 45^o^ in external rotation, elbow at 90^o^, SWT was placed in the direction of calcifications.2500\*0.1, pressure of 2.5 bar41 weekNoneCharrin (2001) \[[@CR22]\]Prospective open design3249.8 ± 5.952.1 ± 48.5Ultrasound was used to identify the lesions and aimed at the calcific deposit at all times.2000\*0.322 or 313.4 ± 6.4 daysNoneCosentino (2003) \[[@CR23]\]RCT3551.815 (10--20)SWT was placed in the direction of the calcification based on sonographic examination1200\*0.2844--7 daysNoneDaecke (2002) \[[@CR24]\]Prospective comparative designGroup A: 56Group B: 5949 (28--77)5 (1--36) yearsSWT was performed after localization of the calcification in 2 planes by fluoroscopy2000\*0.3Group A: 1Group B: 21 weekNone, yesDeBoer (2017) \[[@CR25]\]RCT1453 (95%CI 48, 58)\> 6NR2500\*0.1, pressure of 2.5 bar51 weekNoneDelCastillo-Gonzalez (2016) \[[@CR26]\]RCT8049 ± 7NRThe calcification was identified by fluoroscopy in seated position2000\* 0.28Twice weeklyNoneFarr (2011) \[[@CR27]\]RCT1549.7 ± 9\> 6The calcific deposit was located by fluoroscopy. The computer calculated angle and distance for maximum precision.Group A: 3200\*0.3Group B: 1600\*0.2Group A: 1Group B: 21 weekNone, yesGerdesmeyer (2003) \[[@CR28]\]RCT48 eachHigh: 51.6 ± 8.5Low: 47.3 ± 8.5placebo: 52.3 ± 9.8High: 42.6 ± 23.2Low: 42.8 ± 25.2placebo: 41.3 ± 28.6Using fluoroscopy in prone position as the shoulder was rotated until the calcific deposit was identifiedHigh: 1500\*0.32Low: 6000\*0.08214 daysAll groups received 10 physiotherapy sessions after SWT, noHsu (2008) \[[@CR29]\]RCT3354.4 (30--70)12.3 (6--72)NR1000\*0.55214 daysNone, yesJakobeit (2002) \[[@CR30]\]8053.3\> 6SWT was performed with retroversion and adduction of the shoulder as far as possible under ultrasound monitoring1800\*0.421--54--6 weeksNone, yesKim (2014) \[[@CR31]\]RCT2957.4 (47--78)\> 3SWT was performed in the sitting position by aiming at the maximum sore spot according to anatomic targeting1000\*0.3631 weekNSAIDs, noKransy (2005) \[[@CR32]\]RCT4049.4 (32.4--63.5)30.5 (12--60)In prone position, the calcific deposit had been positioned in the center of the scan unit.2500\*0.361NANone, yesLoew (1999) \[[@CR33]\]RCT20 each46 (28--77)36The calcification was visualized using fluoroscopy before and at intervals during treatment.Group 1: 2000\*0.1Group 2,3: 2000\*0.3Group 1,2: 1Group 3: 21 weekNone, yesLowe (1995) \[[@CR34]\]Prospective open design2050 (35--72)\> 12SWT was performed as localization of the calcium deposit was achieved with an image intensifier that was adjusted automatically in two planes. The head was placed in a ventro-lateral position2000\*18--22 kV22 weeksNone, yesMoretti (2005) \[[@CR35]\]Prospective open design5443 (34--66)\> 3NR2500\*0.1143 daysNonePan (2003) \[[@CR36]\]RCT3255.21 ± 2.0124.55 ± 6.45SWT was positioned at the marked painful area as defined by sonography before each treatment2000\*0.26--0.32214 daysNonePigozzi (2000) \[[@CR37]\]Prospective open design1938 (18--69)\> 2NR2000\*0.2181 weekNonePleiner (2004) \[[@CR38]\]RCT23 (31)54 ± 11\> 6SWT was focused on the point of maximum pain2000\*0.28214 daysNoneRompe (1995) \[[@CR39]\]Prospective open design404725 (12--120)SWT was administered once the calcium deposit is situated in the center of the C-arm.1500\*0.281NANone, yesRompe (2001) \[[@CR40]\]prospective quasi-randomized5049.6 ± 7.552.6 ± 54.4SWT was administered once the calcium deposit is situated in the center of the C-arm3000\*0.61NAActive exercise for 4 to 6 weeks, yesSabeti-Aschraf (2005) \[[@CR41]\]RCT25 each52.68 ± 8.19\> 6In group 1, the angle and distance between the SWT and shoulder were adjusted until the patient reported to the point of maximum tenderness. In group 2, the Lithotrack device was used to locate the calcium deposit in the center of a crosshairs by fluoroscopy in 2 planes. The computer calculated the angle and distance to provide maximum precision.1000\*0.0831 weekNoneTornese (2011) \[[@CR42]\]RCT3552.6NRGroup A (Neutral position): the subject lay supine with shoulder in neutral rotation, the arm placed alongside the trunk and the hand resting on the abdomenGroup B (Hyperextended internal rotation): the subject lay supine with shoulder in hyperextension and internal rotation with the hand placed under the buttock and the palm facing down1800\*0.2231 weekNone*NSAIDs* Nonsteroidal Anti-Inflammatory Drugs, *NA* not applicable, *NR* not reported

Plain radiographs obtained at different time points post SWT was the method used to assess imaging outcomes in 21 studies, while two studies used ultrasonography. Four studies reported the change in calcium deposit diameter (mm), 16 studies reported the number of participants demonstrating total calcification resorption and three reported on reduction or fragmentation of the calcium deposit (Table [2](#Tab2){ref-type="table"}). Table 2Imaging outcome measures for rotator cuff calcifying tendinitisAuthor (year)SWT typeComparatorImaging outcomeFollow-upPeriodBaseline - F/U\
Mean ± SD***P*** valueWithin groupBetween groupAlbert (2007) \[[@CR20]\]High SWTLow SWTThe radiological aspects of calcifications (i.e. type, size and location) were determined through lateral and anteroposterior shoulder views in neutral, external and internal rotation. Changes were graded as no resorption, partial resorption and total or subtotal resorption (over 80% reduction of calcified surface on anteroposterior view)3 monthsHigh: 6(15%) had total or subtotal resorption. 3(7.5%) had partial resorptionLow: 2(5%) had total or subtotal resorption. 5(12.5%) had partial resorptionNRNRCacchio (2006) \[[@CR21]\]R-SWTPlaceboThe radiological aspects of calcifications (i.e. type, size and location) were determined through lateral and anteroposterior shoulder views in 45 degrees of external and internal rotation were acquired. Type of calcification was evaluated according to the Gartner and Simons classification. A caliper that evaluated calcification length (in millimeters) was used for size measurement.1 week39(86.6%) had total resorption, 6(13.4%) had partial resorption, while the control group, no complete disappearance of calcifications was observed.The mean Calcium deposits diameter (mm) pre-SWT was 21.3 ± 7.5, post-SWT was 0.85 ± 1.2. In contrast, pre-sham was 19.7 ± 8.3, post-sham was 18.85.8 ± 6.4.\< 0.00\< 0.00Charrin (2001) \[[@CR22]\]F-SWTNoneCalcific deposit appearance was assessed on a plain radiograph in neutral rotation3,6,12,24 weeksAfter 12 weeks, 2/30 had total resorption. 5 deposits had partial resorption.After 24 weeks, 5/29 had total resorption and 2 deposits had partial resorptionNRNACosentino (2003) \[[@CR23]\]F-SWTPlaceboVariations in the dimension of the calcification were evaluated by anteroposterior views. Modification of the calcification (a reduction of size of \> 2 mm) was indicated as disintegration; the total disappearance was indicated as dissolution.1 month11(31%) had total resorption, 14(40%) had partial resorption. Calcification remained unchanged in the control group\< 0.001NRDaecke (2002) \[[@CR24]\]F-SWT1 vs 2 sessionsAnteroposterior radiograph in internal and external rotation was obtained to show obvious changes in the shape and structure (disintegration) or complete resorption of the calcification3,6 months, 4 years30% in group A and 52% in group B had partial or total resorption after 3 months, 47 and 77% after 6 months and 93% for both groups at 4 yearsNR\< 0.046 at 6 monthsDeBoer (2017) \[[@CR25]\]R-SWTUltrasound Needling (UN)Scoring of calcification deposits was assessed through the Gartner Classification of Calcific Tendinitis.6 weeks1/14 (7%) in the R-SWT group had total resorption vs 5/11 (45.5%) in UN groupNR0.029DelCastillo-Gonzalez (2016) \[[@CR26]\]F-SWTUltrasound-guided percutaneous lavage (UGPL)Calcification size measurement was assessed by ultrasound imaging.3,6,12 months55.6% had total resorption by 12 months in the SWT group vs 86.78% in the UGPL group.The mean Calcium deposits diameter (mm) pre-SWT was 10.53 ± 5.29, post-SWT was 4.67 ± 6.08 after 12 months. In contrast, pre-UGPL was 12.075 ± 4.85, post-UGPL was 1.56 ± 2.79.\< 0.01\< 0.01Farr (2011) \[[@CR27]\]F-SWTLow SWTRadiological difference of the calcific deposit was rated as improvement, unchanged or worsening6,12 weeks58% improved in group A compared to 69% in group B after 12 weeks.5 in group A, and 4 in group B had total resorptionNRNRGerdesmeyer (2003) \[[@CR28]\]F-SWTLow SWT and placeboThe radiological aspects of calcifications (i.e. type, size and location) were determined through anteroposterior shoulder views in 45 degrees of external and internal rotation.3,6,12 monthsHigh: 60% had total resorption within 6 months and 86% after 12 months. Low: 21% had total resorption within 6 months and 37% after 12 months. Placebo: 11% had total resorption within 6 months and 25% after 12 months.Calcific deposit size (mm2) mean change from baseline after 12 months was − 162.2 (95%CI − 204 to −120) in the High-SWT group, − 91.5 (95%CI − 148 to − 35.1) low-SWT group and − 46.8 (95%CI −74.3 to −19.3) in the placebo groupNRgroup 1 vs 3 *P* \< 0.01, group 2 vs 3 P = 0.1, group 1 vs 2 *p* = 0.04Hsu (2008) \[[@CR29]\]F-SWTPlaceboAn anteroposterior radiograph with the arm in neutral rotation was obtained. The calcific deposits were categorized according to morphology and size (the longest length of the calcium deposit). Scoring of calcification deposits was assessed through the Gartner Classification of Calcific Tendinitis6 weeks, 3,6,12 months7(21.2%) had total resorption, 11(36.6%) had partial resorption. In the control group, none had total resorption and 2(15.3%) had partial resorption.The mean Calcium deposits diameter (mm) pre-SWT was 11.9 ± 5.4 (3.4--23.5), post-SWT was 5.5 ± 6.3 (0--18.7). In contrast, pre-sham was 10.5 ± 6.4 (2.5--20.4), post-sham was 9.8 ± 5.9 (2.3--21).\< 0.01\< 0.01Jakobeit (2002) \[[@CR30]\]F-SWTNoneDiagnostic ultrasonography and radiography were used to classify the calcareous deposits in 5 categories according to their morphological appearance and size.4 weeks57/80 (71.25%) had total resorption. 16/80 (20%) had partial resorptionNRNAKim (2014) \[[@CR31]\]F-SWTUltrasound NeedlingRadiographic evaluations were performed by standard shoulder anteroposterior radiographs in neutral, internal, and external rotation together with axillary and supraspinatus outlet views to determine the size, morphology, and location of the calcific deposits. Resorption of the calcific deposit was graded as none, partial, or complete.6 weeks, 3,6,12 monthsThe mean Calcium deposits diameter (mm) pre-SWT was 11 ± 1 (4.9--19.3), post-SWT was 5.6 ± 0.8. In contrast, pre-US needling was 14.8 ± 1.7 (6.6--31), post-US needling was 0.45 ± 0.3.In the SWT group, 42.6% had total resorption, 16.7% had partial resorption. In the US needling group 72.2% had total resorption and 11.1% had partial resorption.\< 0.05=0.001Kransy (2005) \[[@CR32]\]F-SWTUltrasound Needling combined with SWTAnteroposterior radiographs were taken in internal and external rotation together with axial and supraspinatus-outlet views to determine the size, morphology and location of the calcific deposits.4.1 ± 0.5In the SWT only group, 13(32.5%) had total resorption, 14 (35%) had partial resorption. In the US needling combined with SWT group 24(60%) had total resorption and 10 (25%) had partial resorption.NS=0.024Loew (1999) \[[@CR33]\]F-SWTLow SWT and controlRadiographs included an anteroposterior view in internal and external rotation and a supraspinatus outlet view. Effective treatment was recorded when the calcification had completely disappeared or showed obvious resorption with inhomogeneity and reduction in size3,6 monthsThere was total resorption in 4/20 in group 1, 11/20 in group 2, 12/20 in group 3, in contrast to 2/20 in the control groupGroup 1 = 0.37Group 2, 3 \< 0.01NRLowe (1995) \[[@CR34]\]F-SWTNoneRadiological assessment of the calcification was made in three different planes.6,12 weeksAfter 12 weeks, changes were seen in 12 patients; 7 showed a total resorption of the calcium depositsNRNAMoretti (2005) \[[@CR35]\]F-SWTNoneRadiographs in anteroposterior of shoulder, acromial outlet view and sonography were evaluated to study the type of calcium deposit according to DePalma criteria1,6 months29/54 (54%) had total resorption and 19/54 (35) had partial resorption after 1 month. These findings appeared unvaried at 6 months follow-upNRNAPan (2003) \[[@CR36]\]F-SWTTENSHigh-resolution ultrasonography (HRUS) was used for imaging measurements. The morphology of calcific plaque of the shoulder on HRUS was classified into 4 types: (1) arc-shaped (echogenic arc with clear shadowing), (2) fragmented (at least 2 separated echogenic plaques with or without shadowing) or punctuated (tiny calcific spots without shadowing), (3) nodular (echogenic nodule without shadowing), and (4) cystic types (bold echogenic wall with echo-free content)2,4,12 weeksThe mean of difference in Calcium deposits diameter (mm) in the SWT group was 4.39 ± 3.76 after 12 weeks. In contrast, the TENS group was 1.65 ± 2.83.16/33(48.5%) changed in the type of calcification In the SWT group while 3/29 (10.3) in the TENS group.\< 0.010.002Pigozzi (2000) \[[@CR37]\]F-SWTNoneRadiological assessment of anteroposterior, internal and external rotation and trans-glenoid projection was performed1 month7/19 (37%) had reduction or fragmentation of the calcium depositNRNAPleiner (2004) \[[@CR38]\]F-SWTPlaceboAnteriorposterior, axial and outlet-view images were used. Changes calcifications were assessed using the Gartner scale in which a score of 1: indicates no change or a worsening, a score of 2: a decrease of at least 50% in the area and density of the calcification, and a score of 3: complete remission of the calcification3,7 months6/31 (19.4%) had total resorption and 6/31 (19.4%) had partial resorption in the SWT group, in contrast to 2/26 (7.7%) had total resorption and 2/26 (7.7%) had partial resorption in the control group after 7 monthsNR=0.07Rompe (1995) \[[@CR39]\]F-SWTNoneOn radiographs, any sign of disintegration was rated as success6,24 weeks4/40 (10%) had total resorption and 17/40 (42.5%) had partial resorption after 6 weeks.After 24 weeks, 6/40 (15%) had total resorption and 19/40 (47.5%) had partial resorptionNRNARompe (2001) \[[@CR40]\]F-SWTSurgical extirpationOn the anteroposterior radiological views, resorption was graded as none, partial, or complete.12 months47% had total resorption and 33% had partial resorption in the SWT group. In the surgical group, 85% had total resorption and 15% had partial resorption. There was no significant difference regarding the radio-morphologic featuresNR\< 0.01Sabeti-Aschraf (2005) \[[@CR41]\]F-SWTNavigation vs feedbackNo change in the radiographs was graded as 4, a 3 indicated slight alteration of the calcium deposit, reduction in deposit size and radiographic density was graded as 2, and a 1 was given if the calcium deposit was no longer evident3 months6/25 (24%) had total resorption and 7/25 (28%) had extensive resorption in the navigation group, in contrast to 1/25 (4%) had total resorption and 5/25 (20%) had partial resorption in the feedback groupNR0.041Tornese (2011) \[[@CR42]\]F-SWTNeutral vs hyperextended internal rotation arm positionChanges between pre- and post-treatment radiographs were graded as no resorption, partial resorption and total or subtotal resorption (\> 80% reduction in calcified surface on anteroposterior view)3 months12/18 (66.7%) had total resorption in the hyperextended internal rotation group, in contrast to 6/17 (35.3%) in the neutral position groupNR\< 0.05*F-SWT* focused SWT, *R-SWT* radial SWT, *NR* not reported, *NS* not significant, *NA* not applicable

The size of calcium deposit was shown to reduce following SWT application (MD 8.44 mm (95%CI 4.30, 12.57), *p* \< 0.001; Fig. [3](#Fig3){ref-type="fig"}) within a period of 1 week \[[@CR21]\], 3 months \[[@CR36]\] and 12 months \[[@CR26], [@CR29], [@CR31]\]. Baseline calcium deposit size was the only covariate to explain the variance related to the effect of SWT (Coeff. 1.38 mm (95%CI 0.98, 1.77) I^2^ = 43.55%, Adj. R^2^ = 99.18%, *p* = 0.002). No variables related to SWT treatment parameters were significant covariates. Fig. 3Forest plot of effect of SWT on Calcium deposit diameter (mm) in rotator cuffcalcific tendinitis.

The reduction in calcium deposit size favored SWT compared to placebo but did not reach statistical significance (MD − 11.26 mm (95%CI -24.68, 2.17), *P* = 0.1) \[[@CR21], [@CR29]\]. However, the effect of SWT on calcium deposit size was less compared to ultrasound-guided needling (MD 4.25 (95%CI 2.27, 6.24), *p* = 0.006), (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR26], [@CR31]\]. Total calcium resorption was reported in 222/559 (35%) shoulders. Total calcium resorption was greater in the SWT group compared to placebo (OR 6.38 (95%CI 1.33, 30.70, *p* = 0.02), but not compared to ultrasound guided-needling (OR 0.27 (95%CI 0.12, 0.64), *p* = 0.003), (Fig. [5](#Fig5){ref-type="fig"}). Fig. 4Forest plot of effect of SWT vs control on Calcium deposit diameter (mm) in rotator cuff calcific tendinitisFig. 5Forest plot of effect of SWT vs control on total calcification resorption in rotator cuff calcific tendinitis

Plantar fasciitis and heel spurs {#Sec15}
--------------------------------

A total of 13 studies (7 RCTs) published between 2008 and 2018 evaluated imaging changes in plantar fasciitis following SWT. The total number of included participants was 359 (365 heels) diagnosed with symptomatic heel pain in addition to imaging features of plantar fascia thickening (\> 4 mm) as the main inclusion criteria. The main exclusion criteria were the presence of systemic disease such as rheumatoid arthritis, diabetes mellitus, vascular abnormalities or neurological impairments.

Eight studies utilized focused-SWT, radial-SWT was used in three studies and one study employed a combined focused and radial SWT type stimulus. The type of SWT was not reported in one study \[[@CR43]\]. The mean SWT shocks per treatment session was 2426.92 ± 965.36 (1000--4000) with a mean EFD of 0.22 ± 0.14 (0.03--0.42) mJ/mm^2^. The mean number of treatment sessions was 3.04 ± 1.67 (1--8) sessions with a mean of 24.79 ± 43.56 (1--140) days between sessions. Only two studies used anesthesia before the application of SWT and four studies employed sonographic guidance to localize the area of application (Table [3](#Tab3){ref-type="table"}). Table 3Characteristics of studies and intervention details for plantar fasciitis and heel spursAuthorStudy designConditionNMean age ±SD or (range)Mean symptoms duration ± SD or (range), monthsArea of SWT applicationDosage in impulses\*EFD (mJ/mm^**2**^)/barNo. of sessionsInterval between sessionsCo- intervention, anesthesiaBicer (2018) \[[@CR44]\]Prospective open designPlantar fasciitis3045.23 ± 8.57\> 6 weeksNR2500\*2--3 bars31 weekNoneChew (2013) \[[@CR45]\]RCTPlantar fasciitis19median and interquartile range: 45 (37--53)median and interquartile range: 18 (7--24)SWT delivered under ultrasound guidance to the painful and thickened region of the plantar fascia at the medial calcaneal tubercle. The patient was positioned prone with the feet over the end of the table2000\*0.4221 weekHome exercise program, noneDaniel-Lucian (2013) \[[@CR43]\]Prospective open designPlantar fasciitis17NR\> 3SWT was applied over the calcaneal plantar side, aponeurosis insertion and plantar aponeurosis4000EFD is NR8Twice a weekNoneGerdesmeyer (2015) \[[@CR46]\]prospective intra-individual controlledHeel spur4553 (28.6--80.1)\> 6SWT localization of the most painful area was achieved with biofeedback mechanism and radiologically controlled. SWT was placed at the origin of the fascia and reached the central calcaneus.2000\*0.3222 weeksNoneHammer (2005) \[[@CR47]\]prospective intra-individual controlledPlantar fasciitis2251.6 (24--79)8.8 (6--12)NR3000\*0.231 weekNoneHocaoglu (2017) \[[@CR48]\]RCTPlantar fasciitis3650.22 ± 8.298 (6--24)Patients were in the prone position. SWT was applied on plantar fascia insertion of the calcaneus2000\*0.1631 weekNoneLai (2018) \[[@CR49]\]RCTPlantar fasciitis4754.53 ± 8.627.94 ± 2.92NR1500\*02922 weeksNoneLee (2003) \[[@CR50]\]RCTCalcaneal bone spurs308NR\> 6SWT was applied from the plantar surface over a 2 cm circular area around the predetermined point of maximal tenderness at the plantar anthesis1500\*0.221 or 23 monthsNone, yesMaki (2017) \[[@CR51]\]Prospective open designPlantar fasciitis2355.3 (16--81)26.9 (4--300)SWT was applied at the plantar fascia attachment under ultrasonic guidance from the medial calcaneus. A second treatment was performed if symptoms persisted at 3 months3800\*0.361 or 23 monthsNoneMoretti (2006) \[[@CR52]\]Prospective open designPlantar fasciitis5435.2 (30--42)\> 6SWT was applied at the medial tubercle of the calcaneus, at the proximal insertion of the plantar fascia or the calcaneal spur, around the point of medial tenderness2000\*0.0441 weekNoneSaber (2012) \[[@CR53]\]RCTPlantar fasciitis3034.27 ± 7.19\> 6SWT was applied in prone position over the area of maximal tenderness and finding by ultrasonography1000--1500\*0.2822 weeksNone, yesSorrentino (2008) \[[@CR54]\]RCTPlantar fasciitis30Total sample = 34 women (56 ± 2.4) and 26 men (52 ± 3.7)4SWT was applied under ultrasonography guidance to locate the calcaneal insertion of the plantar fascia2000\*0.0341 weekNoneUlusoy (2017) \[[@CR55]\]RCTPlantar fasciitis1954.45 ± 6.927 ± 29.79SWT was applied in the prone position into the areas of the painful heel, insertion of plantar fascia on the medial calcaneal area, and myofascial junction at the dorsum of the heel2000\*2.5-bar31 weekContinue previous exercise program, noVahdatpour (2012) \[[@CR56]\]RCTPlantar fasciitis2050.6 ± 10\> 3SWT was targeted to the maximum local tenderness area2000 focused+ 2000 radial\*0.231 weekExercise, NSAIDs, and heel pad for both groups, noYalcin (2012) \[[@CR57]\]Prospective open designHeel spur10850.2 ± 11.327.4 ± 32.8SWT was applied in prone position to the marked tender spot2000\*0.4 (4 bar)51 weekNoneZhu (2005) \[[@CR58]\]Prospective open designPlantar fasciitis12 (18 ft)49.9 (33--63)\> 6SWT was applied to the most painful point (2--3 cm diameter) on the heel1500\*18kv1NANone, yes*NSAIDs* nonsteroidal anti-inflammatory drugs, *NA* not applicable, *NR* not reported

Ultrasonography was the most common method for evaluating the imaging outcomes as reported in nine studies, followed by MRI in four studies. The change in plantar fascia thickness (PFT) was evaluated in eight studies as the most frequently reported imaging outcome (Table [4](#Tab4){ref-type="table"}). Table 4Imaging outcome measures for plantar fasciitis and heel spursAuthor (year)SWT typeComparatorImaging outcomeFollow-upPeriodBaseline - F/U\
Mean ± SD***P*** valueWithin groupBetween groupBicer (2018) \[[@CR44]\]R-SWTNoneMRI was used to assess changes in the soft tissue and BME, plantar fascia thickness (PFT) and the presence of heel spurs. MRIs were scored semi-quantitatively. PFT was measured 1 cm from the insertion and thickness \> 3 mm was considered abnormal3 months12/23 (52.1%) showed improvement in PFT. 21/30 (70%) and 10/19(52.6%) had improvement in soft tissue and BME respectively. No significant change in heel spur\< 0.05NAChew (2013) \[[@CR45]\]F-SWTAutologous Conditioned Plasma (ACP) and conventionalUltrasonography of plantar fascia (PF) was performed to manually measure the point of maximal proximal PFT at the medial calcaneal tubercle insertion site.1,3,6 monthsThe median PFT improvement in the ACP group at the 6-month follow-up was 1.3 mm compared with the SWT and conventional treatment groups, which both showed improvements of 0.6 mm.NRSWT vs conventional treatment =0.934ACP vs SWT = 0.027Daniel-Lucian (2013) \[[@CR43]\]NRNoneUltrasonography was used to measure PFT3 monthsThe mean PFT decreased from 5.84 to 5.21 in the females, and from 5.87 to 5.14 in the male subjectsNRNRGerdesmeyer (2015) \[[@CR46]\]F-SWTNoneMeasurements of bone mass density (BMD) and bone mass concentration (BMC) were performed with a Lunar DEXA. The square-shaped analysis field (Region of Interest, ROI) was placed in the cancellous part of the calcanei and BMD and BMC were measured.6,12 weeksThe mean BMD (g/cm2) values changed from 0.5 ± 0.1 to 0.557 ± 0.1 in the SWT group and from 0.54 ± 0.1 to 0.52 ± 0.09 in the control group after 12 weeks.The mean BMC (g) values changed from 2.03 ± 0.38 to 2.22 ± 0.38 in the SWT group and from 2.16 ± 0.4 to 2.08 ± 0.36 in the control group after 12 weeks0.001\< 0.01Hammer (2005) \[[@CR47]\]F-SWTNoneThe PFT was measured about 2 cm distal of the medial calcaneal tuberosity using ultrasonography6,12,24 weeksThe mean PFT in 16 subjects changed from 5.2 ± 1.5 to 4.4 ± 1 after 6 months. There was no significant change of PFT on the control side\< 0.05\< 0.05Hocaoglu (2017) \[[@CR48]\]R-SWTUltrasound-guided local corticosteroid injectionPFT and its echogenicity were examined through ultrasonography. A linear probe was positioned longitudinally over the medial tubercle of the calcaneus. PFT was measured at the proximal point of insertion of the fascia into the calcaneal tubercle. A PFT of 4 mm was considered evidence of fasciitis.1,3,6 monthsPFT was found to be significantly reduced in both groups at all measurement endpoints compared with baseline with no significant differences between groups\< 0.01\> 0.05Lai (2018) \[[@CR49]\]F-SWTCorticosteroid injectionPFT was measured at the PF insertion 5 mm distal to calcaneus tuberosity using ultrasonography.1,3 monthsAt 4th week, the mean PFT changed in SWT group from 0.37 ± 0.07 to 0.46 ± 0.08 cm, and in the CSI group from 0.38 ± 0.06 to 0.43 ± 0.09 cmAt the 12th week, the mean PFT changed in the SWT group from 0.37 ± 0.07 to 0.38 ± 0.07 cm, and the CSI group from 0.38 ± 0.06 to 0.39 ± 0.07 cmNRAt 4th week =0.048At 12th week =0.326Lee (2003) \[[@CR50]\]R-SWTPlaceboAxial, lateral, and oblique radiographs of the calcaneus were performed to examine the presence of any osseous abnormalities of the calcaneus or for the presence of inferior calcaneal spurs3,12 months205/308 (67%) in the EWST group had an inferior calcaneal spur. In the sham treatment group, 78/127 (61%) had a spur.No patient treated with SWT had subsequent fragmentation or disappearance of the heel spur at 3 or 12 months. Similarly, no patient had evidence of reactive new bone formation in or around the spur, nor apparent elongation of the spurNRNRMaki (2017) \[[@CR51]\]F-SWTNoneOn MRI, 4 items were examined: PFT, high-signal intensity area (HSIA) inside the PF, edema around the PF, and BME of the calcaneus. For the PFT, the maximum diameter of the PF at the calcaneal attachment was measured on T1-weighted coronal images.6 monthsThe mean PFT changed from 4.4 ± 1.6 to 4.6 ± 1.8 after 6 months.The numbers of feet showing HSIA inside the PF changed from 15 to 6, in edema around the PF from 16 to 2, and in BME of the calcaneus from 11 to 4.\> 0.05NAMoretti (2006) \[[@CR52]\]F-SWTNoneA lateral weight-bearing X-ray of the foot and ultrasound evaluation was performed.45 days, 6,24 monthsThere was no heel spur fragmentation observed. The ultrasound evaluation at 24 months showed a complete disappearance of the inflammatory signs in 33(61%) patients.NRNASaber (2012) \[[@CR53]\]F-SWTUltrasound-guided local corticosteroid injectionPFT was measured at the thickest portion from the base of the medial calcaneal tubercle where a bright echogenic line was easily visible using ultrasonography20 (12--24) weeksThe mean PFT in the SWT group changed from 5.93 ± 0.54 to 3.37 ± 0.42, and in the ultrasound guided injection group from 5.96 ± 0.46 to 3.54 ± 0.31\< 0.01=0.079Sorrentino (2008) \[[@CR54]\]F-SWTCorticosteroid injectionUltrasonography was performed in prone position with ankles dorsiflexed. The focus was adjusted to the depth of the PF. The sonographic diagnosis established based on: 1) fascial thickening \> 5 mm, 2) biconvex morphology and 3) abnormal fascial echostructure, specifically hypoechogenicity, heterogeneity and ill-defined margins. PFT was measured 1 cm from the calcaneal insertion with electronic calipers6 weeksIn the SWT group, PFT with perifascial edema was reduced to 4.6 ± 0.6 mm and up to 4 ± 0.3 mm among PFT without perifascial edema.In the corticosteroidInjection, PFT with perifascial edema was reduced to4.3 ± 0.4 mm and up to 4.6 ± 0.4 mm among PFT without perifascial edemaNRNRUlusoy (2017) \[[@CR55]\]R-SWTlow-level laser therapy (LLLT) and therapeutic ultrasound (US)The maximum thickness of the proximal PF where it attaches to the calcaneus was measured using electronic calipers on fluid-sensitive MRI sequences in the sagittal and coronal planes. The intrafacial and perifacial soft tissue edema and calcaneal BME were assessed in the sagittal plane on short tau inversion recovery sequences, and the presence of the calcaneal spurs was evaluated on T1-weighted sequences1 monthThe mean PFT in the SWT group changed from 5.17 ± 0.89 to 4.31 ± 0.82, in the LLLT group from 4.33 ± 0.59 to 3.75 ± 0.69, and in the US group, from 4.76 ± 0.72 to 3.99 ± 0.62 seen on MRI coronal plane\<.01NSVahdatpour (2012) \[[@CR56]\]F-SWT and R-SWTPlaceboSagittal imaging of the PF was performed with the ultrasound transducer aligned along the longitudinal axis of the aponeurosis. PFT was measured about 2 cm distal of the medial calcaneal tuberosity. Qualitative assessment was performed including echogenic appearance of plantar fascia and its fibrillary pattern3 monthsThe mean PFT in the SWT group changed from 4.1 ± 1.3 to 3.6 ± 1.2, in the placebo group from 4.1 ± 0.8 to 4.5 ± 0.9\<.01=0.02Yalcin (2012) \[[@CR57]\]R-SWTNoneLateral radiographs evaluated variations in the dimensions of calcaneal spurs. The radiographic variations included classification as reductions in the dimensions and the angle of calcaneal spursNRNo significant disappearance of heel spurs, but 19(17.6%) had a decrease in the angle of the spur, 23(21.3%) had a decrease in the dimensions of the spur, and 1(0.93%) had breakage of the spurNRNAZhu (2005) \[[@CR58]\]F-SWTNonePrior to MRI, a vitamin E capsule was taped to the heel that could be readily seen on MRI, where the point of maximal intensity of pain was delineated with a permanent marker. MRI assessed the presence and severity of soft tissue and calcaneal marrow edema, heel spur and PFT.24 h16/18(89%) had subcutaneous soft tissue and perifascial edema before SWT. After SWT, all 18 showed subcutaneous soft tissue and perifascial edema. Calcaneal marrow edema was seen in 8 heels. After SWT, edema increased in 1 heel and 1 new heel edema was developed.Heel spur was seen in 9(50%) that was unchanged.17(94%) had an abnormal PFT (\> 4 mm) before SWT that remained unchanged following SWTNRNA*BME* bone marrow edema, *F-SWT* focused SWT, *R-SWT* radial SWT, *NA* not applicable, *NR* not reported, *NS* not significant

There was an overall reduction in PFT following SWT application (MD 0.92 mm (95%CI 0.03, 1.81), *p* = 0.04; Fig. [6](#Fig6){ref-type="fig"}) at 4 weeks \[[@CR55]\], 6 weeks \[[@CR54]\], 3 months \[[@CR49], [@CR53], [@CR56]\] and 6 month follow-up \[[@CR47], [@CR51]\]. Subgroup analysis showed greater reduction in PFT using radiological guidance (MD 1.31 mm (95%CI 0.49, 2.13), *p* = 0.002) versus no guidance (MD 0.47 mm (95%CI -0.28, 1.21), *p* = 0.22) (Fig. [7](#Fig7){ref-type="fig"}). Baseline PFT was the only covariate to explain the variance related to the effect of SWT (Coeff. -1.06 mm (95%CI − 1.59 to − 0.53) I^2^ = 78%, Adj. R^2^ = 85.10%, *p* = 0.004). No variables related to SWT treatment parameters were significant covariates. The reduction of PFT favored SWT compared with corticosteroid injection (MD − 0.3 mm (95%CI -0.62-0.02), *p* = 0.07) \[[@CR49], [@CR53], [@CR54]\] and over placebo control (MD − 0.9 mm (95%CI − 1.56 to − 0.24), *p* = 0.007) \[[@CR56]\]. However, the effect of SWT on PFT was less compared to low-level laser therapy and therapeutic ultrasound (MD 0.43 mm (95%CI 0.09, 0.78), *p* = 0.01) \[[@CR55]\] (Fig. [8](#Fig8){ref-type="fig"}). Fig. 6Forest plot of effect of SWT on plantar fascia thickness (mm)Fig. 7Forest plot of effect of SWT on plantar fascia thickness (mm) based on radiological guidanceFig. 8Forest plot of effect of SWT vs control on plantar fascia thickness (mm)

The bone resorption effect of SWT on calcaneal spurs was evaluated in three studies (1 RCT) with a total of 461 participants. Chronic symptomatic heel pain (\> 3 months) and radiological evidence of a calcaneal spur were the main inclusion criteria. Radial SWT was used in two studies and one study employed focused SWT. None of the studies utilized radiological guidance and only one study used anesthesia \[[@CR50]\]. The range of delivered shocks was 1500--2000 shocks carried in 1--5 sessions with 7--30 days interval between each session (Table [3](#Tab3){ref-type="table"}).

Morphological changes in calcaneal spurs were evaluated using plain radiographs in two studies, while one study \[[@CR46]\] measured bone mineral density (BMD) and bone mineral content (BMC) using DEXA scanning. None of the studies reported calcaneal spur fragmentation or significant reduction of the spur dimensions \[[@CR50], [@CR57]\]. However, both BMD and BMC demonstrated statistically significant improvement following focused SWT after a 12 week follow-up period, indicating an osteogenic effect \[[@CR46]\] (Table [4](#Tab4){ref-type="table"}).

Osteonecrosis of the femoral head {#Sec16}
---------------------------------

The effects of SWT on osteonecrosis of the femoral head (ONFH) were evaluated in 12 studies (4 RCTs) published between 2001 and 2018. These studies included 325 (404 hips) participants with stage I-III ONFH according to the Association Research Circulation Osseous (ARCO) classification as the main inclusion criterion, except for one study \[[@CR59]\] that included ARCO stage I only. The main exclusion criteria were late ARCO stages, infection, advanced arthritis, neoplastic disease or blood coagulation disorders.

All of the included studies employed focused SWT with a mean EFD of 0.57 ± 0.06 (0.47--0.62) mJ/mm^2^ and a mean of 4867.86 ± 1469.64 (2000--6000) shocks. All of the included studies delivered the treatment over one session, except Vulpiani et al. \[[@CR60]\] who provided treatment over four sessions and D'Agostino et al. \[[@CR59]\] over two sessions (2--3 days interval). Anesthesia was used in eight studies and radiological guidance was implemented in nine studies to accurately target the site of lesion (Table [5](#Tab5){ref-type="table"}). Table 5Characteristics of studies and intervention details for osteonecrosis of the femoral head (ONFH)Author (year)Study designNMean age\
±SD or (range)Mean symptoms duration ± SD or (range), monthsArea of SWT applicationDosage in impulses\*EFD (mJ/mm^**2**^)/barNo. of sessionsInterval between sessionsCo- intervention, anesthesiaAlgarni (2018) \[[@CR61]\]Prospective open design21 (33 hips)37.5 ± 4.86 ± 3The hip was fixed in adduction and internal rotation, ONFH was marked using fluoroscopy in 2--3 points depending on the size of the lesion3000--4500 (1500 pulses for each 2--3 point)\* 26 kV1NANone, yesChen (2009) \[[@CR62]\]Prospective comparative design1742.9 ± 9.311.3 ± 3.4Four points with 1 cm apart within the junctional zone were chosen with a metallic pin under C-arm control, and the corresponding locations were marked on the skin in the groin area. The depth of treatment was adjusted until the two ring markers of the device synchronized under C-arm imaging1500\*0.62 each of the four sites1NANone, yesD'Agostino (2014) \[[@CR59]\]Prospective open design2043.234.2 (4--7) weeksNR4000\*0.522 daysNoneHsu (2010) \[[@CR63]\]RCT35 (48 hips)39.6 ± 11.97.2 ± 2.9The hip joint was properly positioned by abduction and internal or external rotation. The junctional zone between avascular and normal bones of the femoral head was delineated with C-arm imaging1500\*0.62 each of the four sites1NANone, yesLudwig (2001) \[[@CR64]\]Prospective open design2254.9 ± 12.3NRNR4000\*0.621NANoneVulpiani (2012) \[[@CR60]\]Prospective open design36Stage I: 49.3 ± 11.9Stage II: 52.7 ± 14.6Stage III: 45.9 ± 14.1Stage I: 4.3 ± 2.4Stage II: 9.3 ± 4.6Stage III: 14.7 ± 5.9SWT was focused around (on the margins of) the necrotic bone of the femoral head under radiographic guidance2400\*542--3 daysNoneWang (2016) \[[@CR65]\]RCT33 (42 hips)41.8 ± 9.19.3 ± 8.4Both legs were properly positioned. Under C-arm and MRI guidance, the junctional zone between normal bone and necrotic bone within the femoral head was delineated. Within the junctional zone, four points approximately 1 cm apart were chosen under C-arm imaging control and the corresponding locations were marked on the skin in the groin areaGroup A: 2000\*0.51Group B: 4000\*0.51Group C: 6000\*0.511NANone, YesWang (2012) \[[@CR66]\]Prospective comparative design23 (29 hips)NRNRNR6000\*0.4741NANoneWang (2009) \[[@CR67]\]Prospective comparative designTotal 39, 15(26 hips) with SLE, 24(29 hips) controlsSLE group: 32.33 ± 8.97Non-SLE group: 36.47 ± 8.95SLE group: 6.88 ± 2.63Non-SLE group: 7.1 ± 2.79Four points with 1 cm apart within the junctional zone were chosen with a metallic pin under C-arm control, and the corresponding locations were marked on the skin in the groin area. The depth of treatment was adjusted until the two ring markers of the device synchronized under C-arm imaging1500\*0.62 each of the four sites1NANone, yesWang (2005) \[[@CR68]\]RCT23(29 hips)39.8 ± 12.15.9 ± 4.5SWT was applied in the supine position. The hip was positioned in adduction and internal rotation. In patients with a stage-II or III lesion, the junctional zone between avascular and vascular bone of the femoral head was delineated under c-arm control. Four focal points 1 cm apart, within the junctional zone were selected, and the corresponding locations on the skin in the groin area were marked. In patients with a stage-I lesion, the junctional zone was selected on the basis of findings on MRI1500\*0.62 each of the four sites1NANone, YesWang (2008) \[[@CR69]\]RCT25 (30 hips)38.6 ± 12.67.5 ± 3The junctional zone between the avascular and normal bones of the femoral head was delineated with C-arm imaging. Four points with 1 cm apart within the junctional zone were chosen with a metallic pin under C-arm control, and the corresponding locations were marked on skin in the groin1500\*0.62 each of the four sites1NANone, yesWang (2011) \[[@CR70]\]Prospective open design35 (47 hips)38.8 ± 11.97.4 ± 3The hip joint was properly positioned by adduction and internal or external rotation. Four points with 1 cm apart within the junctional zone were chosen with a metallic pin under C-arm control, and the corresponding locations were marked on the skin in the groin area. The depth of treatment was adjusted until the two ring markers of the device synchronized under C-arm imaging1500\*0.62 each of the four sites1NANone, yes*NR* not reported, *NA* not applicable

Imaging changes of ONFH were measured utilizing MRI in addition to radiography in all included studies to evaluate the lesion size, femoral head congruency, presence of a crescent sign, BME and degenerative changes of the hip joint. The percentage of change in the osteonecrosis lesion size was reported in eight studies (Table [6](#Tab6){ref-type="table"}). Table 6Imaging outcome measures for osteonecrosis of the femoral head (ONFH)Author (year)SWT typeComparatorImaging outcomeFollow-upPeriodBaseline - F/U\
Mean ± SD***P*** valueWithin groupBetween groupAlgarni (2018) \[[@CR61]\]F-SWTNoneAnteroposterior and lateral radiographs were obtained to assess the size of the lesion, the extent of subchondral bone collapse, and the presence of degenerative changes in the hip joint. MRI was performed to evaluate BME, the size of the lesion, femoral head congruency, the presence of a crescent sign, and degenerative changes in the hip joint6,12,24 monthsThe mean size of the lesion (%) over the femoral head pre-SWT was 59 ± 32 and post-SWT was 28 ± 16.Significant reduction in BME was noted following SWT*p* = 0.24NAChen (2009) \[[@CR62]\]F-SWTTotal hip arthroplastyMRI were assessed for the congruency of the femoral head, crescent sign, the size and stage of the lesion and bone marrow edema41 ± 7.4 monthThe mean size of the lesion (%) over the femoral head pre-SWT was 23.1 ± 22.2 and post-SWT was 22 ± 23.3.Significant reduction in BME was noted after treatmentlesion size =0.466BME =0.031NAD'Agostino (2014) \[[@CR59]\]F-SWTNoneMRI examination was performed and calculated the edema area using the Sectra PACS software2,3,6 monthsPre-treatment, the mean edema area (mm2) was 981.9 ± 453.2. After 2 months was 469.5 ± 306.8. At 6 months, the mean edema area had reduced to 107.8 ± 248.1.\< 0.01NAHsu (2010) \[[@CR63]\]F-SWTCocktail therapy (SWT, hyperbaric oxygen therapy (HBO), alendronate)Radiographs were used to assess the size and location of the lesion, congruency of the femoral head, the presence of a crescent sign and degenerative changes of the hip joint. MRI was used to evaluate the changes in the size of the lesion, the congruency of the articular surface of the femoral head and BME6,12 monthsThe mean size of the lesion (%) over the total femoral head surface was 28.9 ± 14.9 and 27.4 ± 18 before treatment, and 27.6 ± 14.5 and 26.2 ± 18.5 after treatment for the Cocktail therapy group and SWT alone group, respectively=0.373 for the lesion size, =0.033 for the BME=0.344Ludwig (2001) \[[@CR64]\]F-SWTNoneRadiography and MRI were used to classify the lesions on the ARCO scale1 yearcomplete healing in 4 patients, a significant decrease in the size of the area of poor circulation in 6 patients, and unchanged in 4 patientsNRNAVulpiani (2012) \[[@CR60]\]F-SWTNoneAntero-posterior and lateral radiographs were used to evaluate the size of the lesion, the extent of collapse of subchondral bone and degenerative changes of the hip joint. MRI was used to measure the size of the lesion, assess the congruency of the femoral head, the presence of a crescent sign and/or degenerative changes, with the aim to stage the lesion according to ARCO scale3,6,12,24 monthsAt all follow-up time points, the lesions show no or only minimal changes. Neither regression nor progression of lesions that had been graded before treatment as ARCO stage I and II were seen.NRNAWang (2016) \[[@CR65]\]F-SWTLow vs medium vs high dosage SWTThe necrotic areas of femoral heads on MRI were estimated on a high resolution monitor via the PACS system. The percentage of the infarcted femoral head volume (IFHV) was measured by the infarcted femoral head volume divided by total femoral head volume. BME around the necrotic regions were graded on MRI as follows: grade 0: no BME; grade 1: peri-necrotic; grade 2: edema extending to femoral head; grade 3: edema extending to femoral neck and grade 4: edema extending to intertrochanteric region6 monthsThe mean size of the lesion (%) in group A pre-SWT was 35.1 ± 9.4 and post-SWT was 34.2 ± 5.9, group B pre-SWT was 36.2 ± 8.6 and post-SWT was 36.6 ± 7.7 and group C pre-SWT was 30.5 ± 13.1 and post-SWT was 30.2 ± 7.3.The IFHV of lesion (%) in group A at pre-SWT was 20.8 ± 18.7 and post-SWT was 19.3 ± 19, group B at pre-SWT was 23 ± 14.1 and post-SWT was 22.5 ± 16.4, and group C at pre-SWT was 22.3 ± 15.7 and post-SWT was 18.9 ± 12.5.The stage of the lesion showed no significant differences in all groups. However, BME on MRI was significantly reduced after SWT in group C (*P* = 0.039).\> 0.05 except for the IFHV of lesion in group C = 0.028\> 0.05Wang (2012) \[[@CR66]\]F-SWTCore decompressionMRI was used to examine the size of the lesion, congruency of the femoral head, the presence of a crescent sign, BME and degenerative changes of the hip joint. The percentage of IFHV was measured by IFHV divided by total femoral head volume.1,2,9--8 yearsThe mean size of the lesion (%) over the femoral head pre-SWT was 21 ± 41 and post-SWT was 30 ± 20, 30 ± 20, 26 ± 18 at 1,2, 8--9 years respectively. In the pre-surgical group was 40 ± 23, and post-surgical was 42 ± 15, 41 ± 27, 41 ± 4 at 1,2, 8--9 years respectively.\> 0.05\< 0.05 for the size of the lesion and reduction of BME after SWTWang (2009) \[[@CR67]\]F-SWTNoneRadiographs were used to assess the size of the lesion, congruency of the femoral head, the presence of a crescent sign and degenerative changes. MRI was used to evaluate the changes in lesion size, the congruency of the articular surface and BME.1,3,6,12,24 monthsThe mean size of the lesion (%) over the femoral head pre-SWT in the SLE group was 34.8 ± 21.1 and 28.7 ± 14.2 post-SWT, in the Non-SLE group, pre-SWT was 32.9 ± 22.4 and post-SWT was 26.7 ± 12.9. both groups showed significant reduction of BME following SWT\> 0.05\> 0.05 for the size of lesion and \< 0.05 for reduction of BMEWang (2005) \[[@CR68]\]F-SWTcore decompression and bone-graftingRadiographs of the hip joint were used to evaluate the size of the lesion, the extent of collapse of subchondral bone, and degenerative changes of the hip joint. MRI was used to examine the size of the lesion, the congruency of the femoral head, the presence of a crescent sign, BME, and degenerative changes of the hip joint3,6,12,24 monthsThe mean size of the lesion (%) over the femoral head pre-SWT was 61 ± 41 and post-SWT was 30 ± 20 at 24 months follow-up. In contrast, the pre-surgical was 40 ± 23 and post-surgical was 41 ± 27.In the SWT group, 5 lesions (3 stage I and 2 stage II) regressed and 4 (2 stage II and 2 stage III) progressed. In the surgical group, 4 lesions regressed, 15 (14 stage II and 1 stage I) progressed, and 9 were unchanged=0.282\< 0.01Wang (2008) \[[@CR69]\]F-SWTSWT + alendronateRadiographs of the hip joint were used to assess the size of the lesion, congruency of the femoral head, the presence of a crescent sign and degenerative changes of the hip joint. MRI was used to examine the size of the lesion, the congruency of the femoral head, the presence of a crescent sign, BME, and degenerative changes of the hip joint3,6,12,24 monthsThe mean size of the lesion (%) over the femoral head pre-SWT was 27.7 ± 15.5 and post-SWT was 25.7 ± 16.2 at 6 months follow-up. In contrast, the pre-SWT+ alendronate group was 32.6 ± 19.9 and post- SWT+ alendronate was 29.32 ± 21.99.Significant reduction in BME was noted in both groups.=0.6790.145Wang (2011) \[[@CR70]\]F-SWTNoneRadiographs in AP and lateral views were used to assess the size of the lesion, congruency of the femoral head, the presence of a crescent sign and degenerative changes. MRI was used to evaluate the size of the lesion, the collapse of femoral head and BME.6,12 monthsThe mean size of the lesion (%) over the femoral head pre-SWT was 27.23 ± 18.9 and 27.04 ± 19.17 post-SWT. Significant improvement in BME was noted following SWT\> 0.05 for the size of lesion and = 0.04 for reduction of BMENA*BME* bone marrow edema, *F-SWT* focused SWT, *R-SWT* radial SWT, *NR* not reported, *NS* not significant, *NA* not applicable

The size of the lesion (%) showed modest reduction following SWT application with marginal statistical significance (MD 4.84% (95%CI -0.06-9.75), *p* = 0.05; Fig. [9](#Fig9){ref-type="fig"}) at 6 months \[[@CR65]\], 12 months \[[@CR70]\], 2 years \[[@CR61], [@CR63], [@CR66]--[@CR69]\] and 3 years \[[@CR62]\] follow-up. Baseline lesion size was the only covariate to explain the variance related to the effect of SWT (Coeff. 0.87% (95%CI 0.48, 1.26) I^2^ = 6.2%, Adj. R^2^ = 93.77%, *p* = 0.001). No variables related to SWT treatment parameters were significant covariates. The reduction in the lesion size generally favored SWT compared to other interventions such as core decompression \[[@CR66], [@CR68]\], cocktail therapy \[[@CR63]\] and SWT combined with alendronate \[[@CR69]\] with an overall MD -8.50% (95%CI − 16.40 to − 0.59), *p* = 0.04; Fig. [10](#Fig10){ref-type="fig"}. Fig. 9Forest plot of effect of SWT on femoral head necrosis lesion size (%)Fig. 10Forest plot of effect of SWT vs control on femoral head necrosis lesion size (%)

Miscellaneous conditions {#Sec17}
------------------------

The remaining musculoskeletal conditions evaluated with imaging measures following SWT were fracture non-union \[[@CR71]--[@CR74]\], lateral epicondylitis \[[@CR75], [@CR76]\], knee osteoarthritis related BME \[[@CR77], [@CR78]\], Achilles tendinopathy \[[@CR79]\], post-traumatic myositis ossificans \[[@CR80]\], arthroscopic rotator cuff repair \[[@CR81]\] and Kienbock's disease \[[@CR82]\]. Description of these studies is provided in Additional file [3](#MOESM3){ref-type="media"}.

Discussion {#Sec18}
==========

The aim of the current systematic review and meta-analysis was to evaluate changes in the morphology of musculoskeletal structures as measured by imaging following a SWT (focused and radial) intervention. Overall, there was a tendency for SWT to demonstrate morphological changes among most of the included musculoskeletal conditions based on different quantitative imaging methods. These tissue changes tended to favor SWT over placebo or other comparators except for rotator cuff calcific tendinitis that favored ultrasound guided needling over SWT. Interestingly, SWT type (radial and focused) and the therapeutic dosage parameters did not appear to have a significant influence on the evaluated imaging outcomes according to our subgroup and meta-regression analyses. Also, the utilization of imaging guidance and use of anesthesia had no clear impact on the evaluated imaging outcomes. The baseline size of the lesion was the only factor that explained the heterogeneity in our findings. However, these results should be interpreted with caution due to the relatively small overall number of studies and several potential sources of heterogeneity such as variation in study design, variation in imaging methods and measures, time period for imaging follow-up, high risk of bias and the small number of trials included in the subgroup and meta-regression analyses. In addition, SWT device related factors may contribute to the heterogeneity such as different SWT types. Further research is required to clearly determine whether there are differences in response to focused or radial SWT for different conditions.

Our meta-analysis data on the effect of SWT on rotator cuff calcific tendinitis were comparable to a recent meta-analysis \[[@CR4]\] that reported total resorption occurred more commonly using high- versus low-energy SWT at 3 months (OR: 3.4 (95% CI 1.35,8.58); *p* = 0.009) based on 3 included studies of 163 participants. In addition to reporting the chances of total resorption versus control, the current meta-analysis has also reported within and between groups changes in the size of the calcium deposit diameter that have not been reported previously. A small number of studies (5/23) reported quantification of the change in the size of calcium deposit diameter, which limited the power of the current meta-analysis. Out of the five included studies in the meta-analysis, Cacchio et al. \[[@CR21]\] reported the highest rate of total resorption (86.6%) and reduction in calcification deposit size MD = 20.45 mm (18.23, 22.67) at one week follow-up using a radial SWT device. The authors themselves did not expect this high rate of resorption and attributed it to the feature of radial SWT that insures the whole calcification area is included inside the wave propagation area. The only available included comparable study is by De Boer et al. \[[@CR25]\] that also used a radial SWT device with similar treatment parameters demonstrating a total resorption of only 7% at six weeks. Our data comparison could provide an explanation related to the initial size of the calcium deposit that was exceptionally high in the Cacchio et al. \[[@CR21]\] study (21.3 ± 7.5 mm), which was the only significant predictor in our meta-regression analysis. Larger deposits being more responsive to treatment.

According to our meta-analysis data, SWT demonstrated significant reduction in PFT and associated calcaneal BME. The reduction in PFT was greater when utilizing radiological guidance, which might be due to more consistent targeting of the SWT to the affected tissue area and avoiding surrounding areas. Although one study \[[@CR55]\] using radial SWT showed greater reduction in PFT over focused or combined SWT, these results should be interpreted with caution based on the small number of studies included in the subgroup analysis. Despite the observed overall reduction in PFT in our review that can be correlated with the improvement in chronic plantar pain \[[@CR9]\], it remains unclear whether the type of SWT generation device is an important factor for providing the best outcomes \[[@CR2]\].

Our meta-analysis data revealed non-significant reduction in the lesion size with high-over medium and low-dosage SWT for ONFH. The SWT dose parameters were fairly consistent among all the included studies. This could be attributed to the same research group implementing similar treatment protocols. There are no previously published reviews or meta-analyses reporting on imaging changes following SWT among patients with ONFH to allow results comparisons. However, the observed modest reduction in the size of the lesion could be correlated with a recently published meta-analysis \[[@CR8]\] that reported significant differences between SWT and control groups in pain rating and motor function measures.

Overall, the reported studies support changes in morphological features based on imaging findings that may reflect changes in underlying pathophysiological processes. It would appear that SWT has a clear influence on the morphology of the reported conditions, although for some conditions there is evidence to suggest that other treatments may have a greater influence on the underlying pathophysiology and associated morphological changes.

Limitations of the study {#Sec19}
------------------------

Our aim was to include studies on all kinds of relevant musculoskeletal conditions that had been treated with any type of SWT and reporting any imaging outcomes. We conducted a comprehensive search strategy by including all possible synonyms to avoid missing any potential relevant trials, hence reducing publication bias. To date, we are not aware of any previous systematic reviews that evaluated changes in musculoskeletal conditions based on imaging outcomes following SWT interventions. Publication bias was not evaluated as there were \< 10 trials for each included condition; hence, the power of the test would be very low to distinguish real asymmetry from chance.

The risk of bias scores were 60% for the RCT studies and 74% for non-RCT studies indicating relatively high risk of bias. Participant blinding, allocation concealment, study size calculation and other sources of bias (defined according to imaging assessment accuracy) were the lowest scored items. Of particular interest to this review, the accuracy of imaging measurements was questionable in some cases due to the under-reporting of details pertaining to measurement standardization. It was decided that meeting a minimum of two out of an a priori set of four criteria related to imaging accuracy would be used for judging risk of bias based on imaging accuracy. These criteria were based on providing details on the experience or specialty of the radiologist in musculoskeletal imaging, details of the imaging procedure to insure participant's consistent position during all image acquisition, prior testing or training of the assessor to ensure reliability and reporting the score of measurements based on the average of multiple measurements.

Future research recommendations {#Sec20}
-------------------------------

Current available research has provided preliminary evidence related to the capacity of SWT to influence underlying pathophysiological processes in various musculoskeletal conditions as demonstrated through changes in imaging. However, considering more standardized and reliable quantitative imaging measures as a primary outcome would be warranted in future research. This can be achieved through improving the imaging outcomes assessment methodology to ensure consistent and valid reporting based on our suggested criteria for imaging assessment accuracy. Adopting such criteria can limit the imaging assessment procedure variations as it is challenging to account for it as a covariate in the intervention effect estimate. Imaging endpoints are recommended to be specified and reported to evaluate short, medium and long term changes. Study sample sizes should be calculated based upon imaging parameters as a primary outcome. It would also be of great value if researchers could reach consensus on the optimal imaging modality and relevant imaging measures for each musculoskeletal disorder. Consistency of approach would significantly improve the quality of research.

It was surprising that our comprehensive search strategy did not identify any studies using imaging outcomes for commonly treated tendinopathies such as patellar, proximal hamstring and rotator cuff non-calcific tendinopathies and identified only a few trials for Achilles and wrist extensor tendinopathies. This is an indication of the limited use of imaging as a measure of outcome in addition to the usual clinical outcome measures for this type of condition. Whilst clinical outcomes are clearly of primary importance, imaging does provide a window to assist us in understanding the effects and potential mechanism of action of SWT. Future trials might consider making increased use of imaging outcomes in studies of this nature. This would assist in developing an improved understanding of the extent to which SWT has a therapeutic influence on pathophysiological processes in chronic musculoskeletal disorders.

Conclusions {#Sec21}
===========

The current review has identified some changes in imaging parameters of musculoskeletal conditions in response to SWT. Apparently, dosage parameters of SWT had no clear influence on the imaging outcomes. Also, the utilization of radiological guidance and local anesthesia is questionable. However, the size of lesion is found to be a potential predictor for change in response to SWT. Limitations related to imaging modality selection, timing of imaging and adequate reporting of imaging procedures were factors that influenced the conclusions that could be drawn from the review.
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ARCO

:   Association Research Circulation Osseous

BMC

:   Bone mineral content

BMD

:   Bone mineral density

BME

:   Bone marrow edema

CI

:   Confidence interval

CT

:   Computed tomography

DEXA

:   Dual-energy x-ray absorptiometry

EFD

:   Energy flux density

SWT

:   Shockwave therapy

MD

:   Mean difference

MINORS

:   The methodological index for non-randomized studies

MRI

:   Magnetic resonance imaging

ONFH

:   Osteonecrosis of the femoral head

OR

:   Odds ratio

PF

:   Plantar fascia

PFT

:   Plantar fascia thickness

RCT

:   Randomized controlled trial

SD

:   Standard deviation

US

:   Ultrasonography
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